bone regeneration News
-
UA Little Rock News: NUSHORES biosciences receives $1.7 million grant to study bone regeneration technology
UA Little Rock wrote about us: https://ualr.edu/news/2018/09/20/nushores-biosciences-receives-1-7-million-grant-to-study-bone-regeneration-technology ...
-
OSSIO Receives Vizient Contract for Bio-Integrative Orthopedic Fixation Technology
OSSIO, Inc., an orthopedic fixation technology company, today announced that it has received a contract with Vizient, Inc., making the company’s portfolio of bio-integrative OSSIOfiber products available at negotiated pricing to health care providers in Vizient’s group purchasing organization (GPO) under a three-year contract starting March 1. OSSIO’s contract with Vizient ...
By OSSIO Inc
-
NuShores Biosciences receives new contract for intelligent manufacturing automation of NuCress medical devices
Little Rock, AR – NuShores Biosciences LLC has won a 3-year, $2.8M contract from the Medical Technology Enterprise Consortium (MTEC), a 501(c)(3) biomedical technology consortium associated with the U.S. Army Medical Research and Development Command. The contract will enable NuShores to develop intelligent automated production of its NuCress™ bone void filler scaffold products using ...
-
Molecular Matrix, Inc. Forms Strategic Alliance with Philosys Healthcare
On August 7, 2019, Molecular Matrix, Inc. (MMI) announced the signing of a Memorandum of Understanding (MOU) with Philosys Healthcare Co., Ltd., a biomedical distribution and manufacturing company based in Seongnam, South Korea. MMI is a biotechnology company that began as a startup at UC Davis, and after more than 10 years of research and development has created a scaffold for bone tissue ...
-
NuShores welcomes a new Quality and Regulatory medical device professional to Little Rock
Little Rock, AR – NuShores Biosciences LLC (NuShores), founded and based in Little Rock, Arkansas, announced today that Mr. Sam Monk has accepted the position of Regulatory and Quality Manager and will move to Little Rock from the Seattle area. Mr. Monk will work closely with C-level management, research scientists, manufacturing, and our Quality and Regulatory team and services providers ...
-
OSSIO Awarded FDA 510(k) Clearance for OSSIOfiber Compression Screw Portfolio
OSSIO, Inc., an orthopedic fixation technology company, today announced that its OSSIOfiber® Compression Screw Portfolio has received 510(k) market clearance from the U.S. Food and Drug Administration (FDA) for maintenance of alignment and fixation of bone fractures, comminuted fractures, fragments, osteotomies, arthrodesis and bone grafts of the upper extremity, fibula, knee, ankle and foot ...
By OSSIO Inc
-
Biomatlante receives MDSAP Accreditation
Biomatlante, a world leader in synthetic bone regeneration technologies, is pleased to announce the obtention of the MDSAP* accreditation on the new ISO 13485:2016 Certificate. The Medical Device Single Audit Program (MDSAP) is an international program for assessing the quality management systems of medical device manufacturers who market their products in Australia, Brazil, Canada, Japan and/or ...
-
Synergy Biomedical Announces Publication of Core Scientific Study on Its BioSphere® Bone Graft Technology
Synergy Biomedical, LLC, a developer of innovative bone graft products for spine and orthopedic surgery, announced the publication of a basic science study describing the findings and scientific strategies of controlling the bone formation response of bioactive glass. This study was conducted by Synergy’s founder, Mark Borden Ph.D. and a team of clinical and basic science collaborators, and ...
-
NuShores BioSciences attracts medical devices manufacturing professional to Little Rock
Mark Pelo will lead NuShores’ production of NuCress™ bone regenerative product line. Little Rock, AR – NuShores Biosciences LLC (NuShores), founded and based in Little Rock, Arkansas, announced today that Mr. Mark Pelo has accepted the position of Manufacturing Manager and will move to Little Rock from the Pittsburgh area. He will lead NuShores Generation 1 manufacturing of ...
-
ZetaMet™ Receives Breakthrough Device Designation from U.S. Food and Drug Administration (FDA) for Treatment of Metastatic Bone Cancers
The technology is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone Zetagen Therapeutics is developing the therapy for patients living with metastatic bone lesions and other osteologic conditions The Company is targeting its first human clinical trial for metastatic bone lesions to begin in early 2022 Zetagen Therapeutics, a private, ...
-
ZetaMet™ Receives Health Canada Authorization for Phase 2a Study in Treating Metastatic Bone Lesions
Technology is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone Study will examine the safety and efficacy of ZetaMetTM in the treatment of metastatic bone lesions as part of advanced stage cancer therapy Study is targeting Stage 4 breast cancer patients who have metastatic lesions in their spinal vertebrae Zetagen Therapeutics, a private, ...
-
Transparency notification received from Nyenburgh Holding NV
BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces that it has received a transparency notification dated 16 March 2022 indicating that the shareholdings held by Nyenburgh Holding NV have crossed below the minimum threshold of 5%. The notification dated 16 March 2022 contains the ...
-
Congratulations to our winners for August 2018
The ATA Scientific Encouragement Award is hosted four times each year and provides young scientists access to financial assistance to enable them to collaborate with peers at scientific meetings and to launch their careers within their field of study. The topic of our latest competition focused on the strong link between cognitive behaviour and foods. While studies continue to show evidence that ...
-
Bone Therapeutics to host Annual General Meeting and Extraordinary General Meeting on 8 June 2022
BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics, invites its shareholders and the holders of registered subscription rights and registered convertible bonds of the Company to the Annual General Meeting to be held on Wednesday 8 June 2022 as from 4:00 pm CEST, at Rue Granbonpré 11, Building H, 1435 ...
-
Bone Therapeutics signs definitive subscription agreement for a maximum of EUR 5M convertible bonds facility with ABO
BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics, today announces that it has signed the definitive subscription agreement for a maximum EUR 5 million convertible bonds (CBs) facility arranged by ABO Securities, through its affiliated entity Global Tech Opportunities 15. The proceeds of the financing will contribute to ...
-
CELLINK and Ossiform Enter a Strategic Partnership to launch Ossi Ink, a printable bioink based on Ossiform’s P3D Bone material
CELLINK and Ossiform have entered a strategic partnership to join forces to commercialize a ready-to-print bioink based on Ossiform’s existing biomaterial. Sales of the material will begin in 2024 and will be distributed co-exclusively through CELLINK’s commercial channels. Bone regeneration is one of the fastest growing research disciplines, given the massive impact it can have on ...
By CELLINK
-
Bone Therapeutics announces closing of private placement
BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces the closing of the private placement announced on 3 December 2021, with existing and new institutional investors having purchased 4,832,352 new shares at an issue price of EUR 0.68 per share resulting in gross proceeds of approximately ...
-
Bone Therapeutics enters into exclusive reverse merger discussions with Medsenic
BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, today announces it has entered into a non-binding term sheet and exclusive discussions for a period of three months with the shareholders of Medsenic, a privately held, clinical stage biopharmaceutical company incorporated in France and specialized in ...
-
Locate Bio acquires complementary late stage orthobiologics assets
Locate Bio, an orthobiologics focused regenerative medicine company, today announced the in-licencing of multiple late stage orthobiologics assets from RCSI University of Medicine and Health Sciences. The technologies developed by the RCSI Tissue Engineering Research Group have extensive pre-clinical and human data demonstrating their effectiveness in the treatment of both hard and soft tissues. ...
-
Zetagen Therapeutics, Inc. Receives Patents for Methods in Stimulating Bone Growth Using Small-Molecule
U.S.-based biopharmaceutical company has discovered and patented a novel molecular pathway intended to treat metastatic bone lesions Latest patent issuance furthers the Company’s Global IP strategy Company’s intellectual property pipeline targets other oncologic treatments for Skeletal-Related Events (SRE’s) and osteologic interventions Zetagen Therapeutics, Inc., a ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you